eHealth Initiative

ehidc.org

eHealth Initiative and Foundation (eHI) is a Washington DC-based, independent, non-profit organization whose mission is to drive improvements in the quality, safety, and efficiency of healthcare through information technology. eHI is a multi-stakeholder collaborative, convening executives from every group in healthcare, to discuss, identify, and share best practices that transform the delivery of healthcare. Working with its membership, eHI advocates for the use of health IT that is practical, sustainable, and addresses stakeholder needs, particularly those of patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

QHP CAPITAL ACQUIRES LEXITAS PHARMA SERVICES

Lexitas and QHP Capital | July 08, 2022

news image

QHP Capital the management company for NovaQuest Private Equity announced its acquisition of Lexitas Pharma Services a full-service ophthalmology contract research organization supporting biopharmaceutical and medical device clinical trials. Since 2011, Lexitas has provided clinical trial and medical strategy solutions to biopharmaceutical and medical device companies developing ophthalmic products. The Company provides end-to-end support and development expertise in the ant...

Read More

EPIGENETIC CHANGES MAKE BREAST CANCER CELLS DRUG RESISTANT

LabRoots | January 20, 2020

news image

Changes in the epigenetics - the modifiable chemical tags that can change the genome and gene expression - of breast cancer cells can make them resistant to drugs that are targeting them. This seems to happen to ER+ breast cancer cells, which make up around two of every three cases of breast cancer. This type of cancer can become resistant to the hormonal therapy used to treat it. Breast cancer relapse could be reduced, researchers suggested, if these epigenetic changes can be reversed. Re...

Read More

Business Insights

VIVERA ENTERS $23 BILLION TELEHEALTH INDUSTRY WITH PATENT ALLOWANCE FOR MDZONE

Vivera Pharmaceuticals, Inc. | April 25, 2022

news image

Vivera Pharmaceuticals, Inc. is pleased to announce that it has received a Notice of Allowance for U.S. Patent Application No. 17/066,985 entitled, "Self-Contained, Portable, Sanitization Device and Telemedicine Station," for the Company's MDZone platform from the United States Patent and Trademark Office. This Notice of Allowance indicates that the patent application has passed its examination for issuance. MDZone will be a HIPAA compliant, portable telemedicine sta...

Read More

Pharma Tech

COUR PHARMACEUTICALS RECEIVES FDA FAST TRACK DESIGNATION FOR CNP-104 FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS

COUR Pharmaceuticals | January 11, 2022

news image

COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders, today announced the U.S. Food and Drug Administration granted Fast Track Designation to the Company's investigational therapy CNP-104 for the treatment of Primary Biliary Cholangitis. CNP-104 aims to reprogram the immune system to address autoimmune causes of PBC. "We are pleased to have received Fast Track Designation for CN...

Read More
news image

Business Insights

QHP CAPITAL ACQUIRES LEXITAS PHARMA SERVICES

Lexitas and QHP Capital | July 08, 2022

QHP Capital the management company for NovaQuest Private Equity announced its acquisition of Lexitas Pharma Services a full-service ophthalmology contract research organization supporting biopharmaceutical and medical device clinical trials. Since 2011, Lexitas has provided clinical trial and medical strategy solutions to biopharmaceutical and medical device companies developing ophthalmic products. The Company provides end-to-end support and development expertise in the ant...

Read More
news image

EPIGENETIC CHANGES MAKE BREAST CANCER CELLS DRUG RESISTANT

LabRoots | January 20, 2020

Changes in the epigenetics - the modifiable chemical tags that can change the genome and gene expression - of breast cancer cells can make them resistant to drugs that are targeting them. This seems to happen to ER+ breast cancer cells, which make up around two of every three cases of breast cancer. This type of cancer can become resistant to the hormonal therapy used to treat it. Breast cancer relapse could be reduced, researchers suggested, if these epigenetic changes can be reversed. Re...

Read More
news image

Business Insights

VIVERA ENTERS $23 BILLION TELEHEALTH INDUSTRY WITH PATENT ALLOWANCE FOR MDZONE

Vivera Pharmaceuticals, Inc. | April 25, 2022

Vivera Pharmaceuticals, Inc. is pleased to announce that it has received a Notice of Allowance for U.S. Patent Application No. 17/066,985 entitled, "Self-Contained, Portable, Sanitization Device and Telemedicine Station," for the Company's MDZone platform from the United States Patent and Trademark Office. This Notice of Allowance indicates that the patent application has passed its examination for issuance. MDZone will be a HIPAA compliant, portable telemedicine sta...

Read More
news image

Pharma Tech

COUR PHARMACEUTICALS RECEIVES FDA FAST TRACK DESIGNATION FOR CNP-104 FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS

COUR Pharmaceuticals | January 11, 2022

COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders, today announced the U.S. Food and Drug Administration granted Fast Track Designation to the Company's investigational therapy CNP-104 for the treatment of Primary Biliary Cholangitis. CNP-104 aims to reprogram the immune system to address autoimmune causes of PBC. "We are pleased to have received Fast Track Designation for CN...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us